[Brentuximab vedotin treatment in patients with relapsed or refractory Hodgkin lymphoma. A Hungarian retrospective study].

CONCLUSION: Brentuximab vedotin carries a substantial improvement in the treatment of relapsed or refractory Hodgkin lymphoma. Our results underline prior observations published in the literature. The use of brentuximab vedotin in combination can be beneficial, however further investigation is needed on the subject. Orv Hetil. 2017; 158(41): 1630-1634.
PMID: 29025292 [PubMed - in process]

Source: Orvosi Hetilap - October 1, 2017 Category: General Medicine Authors: Molnár Z, Pinczés LI, Piukovics K, Istenes I, Wolf K, Csukly Z, Szomor Á, Illés Á, Miltényi Z Tags: Orv Hetil Source Type: research